{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:43:54Z","timestamp":1793198634716,"version":"4.5.0"},"reference-count":162,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Drugs and chemotherapeutics have helped to manage devastating impacts of infectious diseases since the concept of \u2018magic bullet\u2019. The World Health Organization estimates about 650,000 deaths due to respiratory diseases linked to seasonal influenza each year. Pandemic influenza, on the other hand, is the most feared health disaster and probably would have greater and immediate impact on humanity than climate change. While countermeasures, biosecurity and vaccination remain the most effective preventive strategies against this highly infectious and communicable disease, antivirals are nonetheless essential to mitigate clinical manifestations following infection and to reduce devastating complications and mortality. Continuous emergence of the novel strains of rapidly evolving influenza viruses, some of which are intractable, require new approaches towards influenza chemotherapeutics including optimization of existing anti-infectives and search for novel therapies. Effective management of influenza infections depend on the safety and efficacy of selected anti-infective <jats:italic>in-vitro<\/jats:italic> studies and their clinical applications. The outcomes of therapies are also dependent on understanding diversity in patient groups, co-morbidities, co-infections and combination therapies. In this extensive review, we have discussed the challenges of influenza epidemics and pandemics and discoursed the options for anti-viral chemotherapies for effective management of influenza virus infections.<\/jats:p>","DOI":"10.3389\/fcimb.2023.1269344","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T05:54:26Z","timestamp":1701237266000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":39,"title":["Antiviral options and therapeutics against influenza: history, latest developments and future prospects"],"prefix":"10.3389","volume":"13","author":[{"given":"Clement","family":"Meseko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin","family":"Sanicas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumari","family":"Asha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanre","family":"Sulaiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binod","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.00450","article-title":"Peramivir: A novel intravenous neuraminidase inhibitor for treatment of acute influenza infections","volume":"7","author":"Alame","year":"2016","journal-title":"Front. Microbiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/jphp.12669","article-title":"A review on antiviral activity of the Himalayan medicinal plants traditionally used to treat bronchitis and related symptoms","volume":"69","author":"Amber","year":"2017","journal-title":"J. Pharm. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/jac\/dkg007","article-title":"Early administration of oral oseltamivir increases the benefits of influenza treatment","volume":"51","author":"Aoki","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/978-1-4757-9209-6_18","article-title":"Update on therapy of influenza and rhinovirus infections","volume":"394","author":"Arruda","year":"1996","journal-title":"Adv. Exp. Med. Biol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/jcm8010006","article-title":"Advancements in nucleic acid based therapeutics against respiratory viral infections","volume":"8","author":"Asha","year":"2018","journal-title":"J. Clin. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/978-3-030-67452-6_4","article-title":"Current insights into the host immune response to respiratory viral infections","volume":"1313","author":"Asha","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3390\/jcm8020192","article-title":"Emerging influenza D virus threat: what we know so far","volume":"8","author":"Asha","year":"2019","journal-title":"J. Clin. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1089\/vim.2015.0013","article-title":"Kolaviron improves morbidity and suppresses mortality by mitigating oxido-inflammation in BALB\/c mice infected with influenza virus","volume":"28","author":"Awogbindin","year":"2015","journal-title":"Viral Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3390\/microorganisms11010183","article-title":"Influenza treatment: limitations of antiviral therapy and advantages of drug combination therapy","volume":"11","author":"Batool","year":"2023","journal-title":"Microorganisms"},{"key":"B10","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1093\/infdis\/159.3.430","article-title":"Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance","volume":"159","author":"Belshe","year":"1989","journal-title":"J. Infect. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1001\/jama.295.8.joc60020","article-title":"Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States","volume":"295","author":"Bright","year":"2006","journal-title":"JAMA"},{"key":"B12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/jmv.22234","article-title":"Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions","volume":"84","author":"Brooks","year":"2012","journal-title":"J. Med. Virol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1124\/jpet.117.240705","article-title":"Danirixin: A reversible and selective antagonist of the CXC chemokine receptor 2","volume":"362","author":"Busch-Petersen","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1128\/AAC.04623-14","article-title":"Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit","volume":"59","author":"Byrn","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/135965359900400302","article-title":"Safety and efficacy of once daily intranasal zanamivir in preventing experimental human influenza A infection","volume":"4","author":"Calfee","year":"1999","journal-title":"Antivir Ther."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002790","article-title":"Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever","volume":"8","author":"Caroline","year":"2014","journal-title":"PloS Negl. Trop. Dis."},{"key":"B17","unstructured":"FluView: week ending2010"},{"key":"B18","unstructured":"Update: Influenza Activity in the United States During the 2016\u201317 Season and Composition of the 2017\u201318 Influenza Vaccine2018"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1021\/jm2013503","article-title":"Design, synthesis, and in vitro biological evaluation of 1H-1,2,3-triazole-4-carboxamide derivatives as new anti-influenza A agents targeting virus nucleoprotein","volume":"55","author":"Cheng","year":"2012","journal-title":"J. Med. Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1371\/journal.ppat.0030141","article-title":"A single mutation in the PB1-F2 of H5N1 (HK\/97) and 1918 influenza A viruses contributes to increased virulence","volume":"3","author":"Conenello","year":"2007","journal-title":"PloS Pathog."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1136\/bmj.326.7401.1235","article-title":"Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials","volume":"326","author":"Cooper","year":"2003","journal-title":"BMJ"},{"key":"B22","doi-asserted-by":"publisher","first-page":"ii5","DOI":"10.1093\/jac\/dkq015","article-title":"Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations","volume":"65","author":"Davies","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S1473-3099(12)70121-4","article-title":"Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study","volume":"12","author":"Dawood","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.3390\/v2061322","article-title":"Historical perspectives in the development of antiviral agents against poxviruses","volume":"2","author":"De Clercq","year":"2010","journal-title":"Viruses"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/nm1477","article-title":"Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia","volume":"12","author":"de Jong","year":"2006","journal-title":"Nat. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40262-017-0564-y","article-title":"Pharmacokinetics of MHAA4549A, an anti-influenza A monoclonal antibody, in healthy subjects challenged with influenza A virus in a phase IIa randomized trial","volume":"57","author":"Deng","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"B27","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJM198209023071002","article-title":"A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection","volume":"307","author":"Dolin","year":"1982","journal-title":"N Engl. J. Med."},{"key":"B28","first-page":"271","volume-title":"Viral Pathogenesis","author":"Douglas","year":"2016"},{"key":"B29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.antiviral.2011.08.002","article-title":"Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo","volume":"92","author":"Droebner","year":"2011","journal-title":"Antiviral Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S1473-3099(14)70821-7","article-title":"Antiviral combinations for severe influenza","volume":"14","author":"Dunning","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162199","article-title":"Experimental treatment of ebola virus disease with brincidofovir","volume":"11","author":"Dunning","year":"2016","journal-title":"PloS One"},{"key":"B32","doi-asserted-by":"publisher","first-page":"ii11","DOI":"10.1093\/jac\/dkq012","article-title":"Oseltamivir in seasonal influenza: cumulative experience in low- and high-risk patients","volume":"65","author":"Dutkowski","year":"2010","journal-title":"J. Antimicrobial Chemotherapy"},{"key":"B33","doi-asserted-by":"publisher","first-page":"24897","DOI":"10.1038\/srep24897","article-title":"Production of potent fully human polyclonal antibodies against ebola zaire virus in transchromosomal cattle","volume":"6","author":"Dye","year":"2016","journal-title":"Sci. Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1750-2659.2012.00392.x","article-title":"Many ways to make an influenza virus\u2013review of influenza virus reverse genetics methods","volume":"7","author":"Engelhardt","year":"2013","journal-title":"Influenza Other Respir. Viruses"},{"key":"B35","unstructured":"FDA approves Rapivab to treat flu infection2014"},{"key":"B36","unstructured":"Drugs2018"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/infdis\/jiy547","article-title":"Phase 2b study of pimodivir (JNJ-63623872) as monotherapy or in combination with oseltamivir for treatment of acute uncomplicated seasonal influenza A: TOPAZ trial","volume":"219","author":"Finberg","year":"2019","journal-title":"J. Infect. Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"8989","DOI":"10.1038\/s41598-018-27224-4","article-title":"The antiviral drug arbidol inhibits zika virus","volume":"8","author":"Fink","year":"2018","journal-title":"Sci. Rep."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.654813","article-title":"Metabolic implications of oxidative stress and inflammatory process in SARS-coV-2 pathogenesis: therapeutic potential of natural antioxidants","volume":"11","author":"Forcados","year":"2021","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.antiviral.2016.07.008","article-title":"JNJ872 inhibits influenza A virus replication without altering cellular antiviral responses","volume":"133","author":"Fu","year":"2016","journal-title":"Antiviral Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.chom.2018.04.015","article-title":"A sialylated voltage-dependent ca(2+) channel binds hemagglutinin and mediates influenza A virus entry into mammalian cells","volume":"23","author":"Fujioka","year":"2018","journal-title":"Cell Host Microbe"},{"key":"B42","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.antiviral.2009.02.198","article-title":"T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections","volume":"82","author":"Furuta","year":"2009","journal-title":"Antiviral Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antiviral Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1304459","article-title":"Human infection with a novel avian-origin influenza A (H7N9) virus","volume":"368","author":"Gao","year":"2013","journal-title":"N Engl. J. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1097\/00126334-200406010-00007","article-title":"Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count","volume":"36","author":"Garcia","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"B46","first-page":"291","article-title":"Chimeric influenza viruses incorporating epitopes of outer membrane protein F as a vaccine against pulmonary infection with Pseudomonas aeruginosa","author":"Gilleland","year":"1997","journal-title":"Behring Inst Mitt"},{"key":"B47","first-page":"36","article-title":"[Mechanisms of arbidole's immunomodulating action]","author":"Glushkov","year":"1999","journal-title":"Vestn Ross Akad Med. Nauk"},{"key":"B48","doi-asserted-by":"publisher","first-page":"4855","DOI":"10.1128\/AAC.48.12.4855-4863.2004","article-title":"Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells","volume":"48","author":"Govorkova","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"B49","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/S0140-6736(98)10190-3","article-title":"Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections","volume":"352","author":"Group","year":"1998","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1080\/19420862.2016.1167294","article-title":"Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A","volume":"8","author":"Gupta","year":"2016","journal-title":"MAbs"},{"key":"B51","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3181\/00379727-73-17652","article-title":"Activity of p-aminobenzaldehyde, 3-thiosemicarbazone on vaccinia virus in the chick embryo and in the mouse","volume":"73","author":"Hamre","year":"1950","journal-title":"Proc. Soc Exp. Biol. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.2147\/DDDT.S46654","article-title":"Safety and efficacy of peramivir for influenza treatment","volume":"8","author":"Hata","year":"2014","journal-title":"Drug Des. Devel Ther."},{"key":"B53","first-page":"44","volume-title":"Antiviral drug resistance","author":"Hay","year":"1996"},{"key":"B54","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1056\/NEJMp068030","article-title":"Antiviral resistance in influenza viruses\u2013implications for management and pandemic response","volume":"354","author":"Hayden","year":"2006","journal-title":"N Engl. J. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/infdis\/jiq012","article-title":"Emerging influenza antiviral resistance threats","volume":"203","author":"Hayden","year":"2011","journal-title":"J. Infect. Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1128\/AAC.18.4.536","article-title":"Enhancement of activity against influenza viruses by combinations of antiviral agents","volume":"18","author":"Hayden","year":"1980","journal-title":"Antimicrob. Agents Chemother."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJM198912213212502","article-title":"Emergence and apparent transmission of rimantadine-resistant influenza A virus in families","volume":"321","author":"Hayden","year":"1989","journal-title":"N Engl. J. Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1056\/NEJM199709253371302","article-title":"Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group","volume":"337","author":"Hayden","year":"1997","journal-title":"N Engl. J. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1128\/AAC.25.1.53","article-title":"Combined interferon-alpha 2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro","volume":"25","author":"Hayden","year":"1984","journal-title":"Antimicrob. Agents Chemother."},{"key":"B60","doi-asserted-by":"publisher","first-page":"454","DOI":"10.7326\/0003-4819-94-4-454","article-title":"Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function","volume":"94","author":"Horadam","year":"1981","journal-title":"Ann. Intern. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrg3922","article-title":"Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms","volume":"16","author":"Hughes","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"B62","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S1473-3099(11)70318-8","article-title":"Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives","volume":"12","author":"Hurt","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"B63","doi-asserted-by":"publisher","first-page":"42","DOI":"10.5214\/ans.0972.7531.200203","article-title":"Kolaviron, isolated from Garcinia kola, inhibits acetylcholinesterase activities in the hippocampus and striatum of wistar rats","volume":"20","author":"Ijomone","year":"2013","journal-title":"Ann. Neurosci."},{"key":"B64","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.antiviral.2006.01.012","article-title":"Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants","volume":"70","author":"Ilyushina","year":"2006","journal-title":"Antiviral Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1177\/0091270009356297","article-title":"Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers","volume":"50","author":"Ishizuka","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S1473-3099(20)30004-9","article-title":"Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Ison","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"B67","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nri3665","article-title":"Innate immunity to influenza virus infection","volume":"14","author":"Iwasaki","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.bmc.2011.10.026","article-title":"Design, synthesis, and evaluation of novel small molecule inhibitors of the influenza virus protein NS1","volume":"20","author":"Jablonski","year":"2012","journal-title":"Bioorg Med. Chem."},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02460-16","article-title":"The PA endonuclease inhibitor RO-7 protects mice from lethal challenge with influenza A or B viruses","volume":"61","author":"Jones","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B70","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3858\/emm.2010.42.2.013","article-title":"Reverse genetic platform for inactivated and live-attenuated influenza vaccine","volume":"42","author":"Jung","year":"2010","journal-title":"Exp. Mol. Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12992-016-0194-4","article-title":"Understanding ebola: the 2014 epidemic","volume":"12","author":"Kaner","year":"2016","journal-title":"Global Health"},{"key":"B72","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s13337-012-0066-3","article-title":"Pandemic influenza A H1N1 (2009) virus: lessons from the past and implications for the future","volume":"23","author":"Khanna","year":"2012","journal-title":"Indian J. Virol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"88","DOI":"10.17116\/terarkh201587188-96","article-title":"[Clinical efficacy of arbidol (umifenovir) in the therapy of influenza in adults: preliminary results of the multicenter double-blind randomized placebo-controlled study ARBITR]","volume":"87","author":"Kiselev","year":"2015","journal-title":"Ter Arkh"},{"key":"B74","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.bbmt.2015.11.015","article-title":"Outcomes of influenza infections in hematopoietic cell transplant recipients: application of an immunodeficiency scoring index","volume":"22","author":"Kmeid","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B75","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jaci.2017.01.007","article-title":"New frontiers in the therapy of primary immunodeficiency: From gene addition to gene editing","volume":"139","author":"Kohn","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169255","article-title":"Interferon beta-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial","volume":"12","author":"Konde","year":"2017","journal-title":"PloS One"},{"key":"B77","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12033-011-9437-z","article-title":"Nucleic acid-mediated cleavage of M1 gene of influenza A virus is significantly augmented by antisense molecules targeted to hybridize close to the cleavage site","volume":"51","author":"Kumar","year":"2012","journal-title":"Mol. Biotechnol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1089\/nat.2013.0432","article-title":"Sequence-specific cleavage of BM2 gene transcript of influenza B virus by 10-23 catalytic motif containing DNA enzymes significantly inhibits viral RNA translation and replication","volume":"23","author":"Kumar","year":"2013","journal-title":"Nucleic Acid Ther."},{"key":"B79","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s00705-018-3708-y","article-title":"The emerging influenza virus threat: status and new prospects for its therapy and control","volume":"163","author":"Kumar","year":"2018","journal-title":"Arch. Virol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.1073\/pnas.78.7.4170","article-title":"Sequences of mRNAs derived from genome RNA segment 7 of influenza virus: colinear and interrupted mRNAs code for overlapping proteins","volume":"78","author":"Lamb","year":"1981","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B81","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1002\/jps.23253","article-title":"Conjugating drug candidates to polymeric chains does not necessarily enhance anti-influenza activity","volume":"101","author":"Larson","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1128\/AAC.02335-12","article-title":"Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus","volume":"57","author":"Lejal","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"B83","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.antiviral.2008.10.009","article-title":"Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol","volume":"81","author":"Leneva","year":"2009","journal-title":"Antiviral Res."},{"key":"B84","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ijid.2016.01.001","article-title":"Virus susceptibility and clinical effectiveness of anti-influenza drugs during the 2010-2011 influenza season in Russia","volume":"43","author":"Leneva","year":"2016","journal-title":"Int. J. Infect. Dis."},{"key":"B85","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11094-005-0036-9","article-title":"Search for new drugs drugs for chemotherapy and prophylaxis of influenza: mechanisms, efficacy, and safety (a review)","volume":"38","author":"Leneva","year":"2004","journal-title":"Pharm. Chem. J."},{"key":"B86","doi-asserted-by":"publisher","first-page":"6659","DOI":"10.1128\/jvi.67.11.6659-6666.1993","article-title":"Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1","volume":"67","author":"Li","year":"1993","journal-title":"J. Virol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1073\/pnas.90.11.5214","article-title":"Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria","volume":"90","author":"Li","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B88","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/095632020501600302","article-title":"Achievements and challenges in antiviral drug discovery","volume":"16","author":"Littler","year":"2005","journal-title":"Antivir Chem. Chemother."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/aps.2013.54","article-title":"Antiviral and anti-inflammatory activity of arbidol hydrochloride in influenza A (H1N1) virus infection","volume":"34","author":"Liu","year":"2013","journal-title":"Acta Pharmacol. Sin."},{"key":"B90","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1021\/acs.molpharmaceut.8b00531","article-title":"A small-molecule compound has anti-influenza A virus activity by acting as a \u2018\u2018PB2 inhibitor\u201d","volume":"15","author":"Liu","year":"2018","journal-title":"Mol. Pharmaceutics"},{"key":"B91","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1128\/jvi.71.5.4062-4070.1997","article-title":"Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus","volume":"71","author":"Luo","year":"1997","journal-title":"J. Virol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3923\/pjbs.2012.754.774","article-title":"Immunomodulatory and therapeutic potentials of herbal, traditional\/indigenous and ethnoveterinary medicines","volume":"15","author":"Mahima","year":"2012","journal-title":"Pak J. Biol. Sci."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1128\/AAC.50.4.1470-1479.2006","article-title":"Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection","volume":"50","author":"Malakhov","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.3201\/eid2310.170679","article-title":"Monitoring avian influenza viruses from chicken carcasses sold at markets, China 2016","volume":"23","author":"Mao","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"B95","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/infdis\/jiu447","article-title":"Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan","volume":"211","author":"Marjuki","year":"2015","journal-title":"J. Infect. Dis."},{"key":"B96","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/infdis\/jit467","article-title":"Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study","volume":"209","author":"Marty","year":"2014","journal-title":"J. Infect. Dis."},{"key":"B97","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S2213-2600(16)30435-0","article-title":"Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial","volume":"5","author":"Marty","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"B98","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1179\/joc.2007.19.3.295","article-title":"Low dose oral combination chemoprophylaxis with oseltamivir and amantadine for influenza A virus infections in mice","volume":"19","author":"Masihi","year":"2007","journal-title":"J. Chemother."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1111\/j.1462-5822.2007.00902.x","article-title":"Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity","volume":"9","author":"Mazur","year":"2007","journal-title":"Cell Microbiol."},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01154-17","article-title":"Phase 2 randomized trial of the safety and efficacy of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human influenza A virus challenge model","volume":"61","author":"McBride","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B101","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.antiviral.2017.11.013","article-title":"Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference","volume":"149","author":"McKimm-Breschkin","year":"2018","journal-title":"Antiviral Res."},{"key":"B102","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S1368-7646(98)80038-1","article-title":"Influenza virus resistance to neuraminidase inhibitors","volume":"1","author":"Mendel","year":"1998","journal-title":"Drug Resist. Update"},{"key":"B103","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3390\/molecules27030658","article-title":"Approaches to the potential therapy of COVID-19: A general overview from the medicinal chemistry perspective","volume":"27","author":"Men\u00e9ndez","year":"2022","journal-title":"Molecules"},{"key":"B104","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1038\/s41598-018-24371-6","article-title":"Evidence of exposure of domestic pigs to Highly Pathogenic Avian Influenza H5N1 in Nigeria","volume":"8","author":"Meseko","year":"2018","journal-title":"Sci. Rep."},{"key":"B105","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1001\/jama.282.1.31","article-title":"Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial","volume":"282","author":"Monto","year":"1999","journal-title":"JAMA"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1093\/infdis\/jis622","article-title":"A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection","volume":"206","author":"Moss","year":"2012","journal-title":"J. Infect. Dis."},{"key":"B107","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/j.1476-5381.2011.01346.x","article-title":"The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections","volume":"164","author":"Muller","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.coph.2016.08.003","article-title":"Antiviral therapies on the horizon for influenza","volume":"30","author":"Naesens","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1093\/jac\/dkt534","article-title":"Antiviral activity of baicalin against influenza virus H1N1-pdm09 is due to modulation of NS1-mediated cellular innate immune responses","volume":"69","author":"Nayak","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"B110","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1099\/0022-1317-83-11-2635","article-title":"A decade after the generation of a negative-sense RNA virus from cloned cDNA - what have we learned","volume":"83","author":"Neumann","year":"2002","journal-title":"J. Gen. Virol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1128\/AAC.00476-09","article-title":"Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro","volume":"53","author":"Nguyen","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009332","article-title":"Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro","volume":"5","author":"Nguyen","year":"2010","journal-title":"PloS One"},{"key":"B113","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3390\/v10010050","article-title":"CRISPR\/cas9-advancing orthopoxvirus genome editing for vaccine and vector development","volume":"10","author":"Okoli","year":"2018","journal-title":"Viruses"},{"key":"B114","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/0166-3542(94)90038-8","article-title":"Aprotinin aerosol treatment of influenza and paramyxovirus bronchopneumonia of mice","volume":"23","author":"Ovcharenko","year":"1994","journal-title":"Antiviral Res."},{"key":"B115","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S1473-3099(02)00185-8","article-title":"World War I may have allowed the emergence of \"Spanish\" influenza","volume":"2","author":"Oxford","year":"2002","journal-title":"Lancet Infect. Dis."},{"key":"B116","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1089\/nat.2012.0359","article-title":"Small interfering RNA targeting the nonstructural gene 1 transcript inhibits influenza A virus replication in experimental mice","volume":"22","author":"Rajput","year":"2012","journal-title":"Nucleic Acid Ther."},{"key":"B117","first-page":"1009","article-title":"Antiviral drugs for viruses other than human immunodeficiency virus","volume-title":"Symposium on Antimicrobial Therapy","author":"Raymund","year":"2011"},{"key":"B118","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1099\/vir.0.19302-0","article-title":"The origin of the 1918 pandemic influenza virus: a continuing enigma","volume":"84","author":"Reid","year":"2003","journal-title":"J. Gen. Virol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1006\/viro.1998.9330","article-title":"Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer","volume":"249","author":"Restifo","year":"1998","journal-title":"Virology"},{"key":"B120","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0166-3542(89)90018-1","article-title":"Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A","volume":"11","author":"Reuman","year":"1989","journal-title":"Antiviral Res."},{"key":"B121","doi-asserted-by":"publisher","first-page":"29798","DOI":"10.1074\/jbc.M109.029470","article-title":"Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level","volume":"284","author":"Rossignol","year":"2009","journal-title":"J. Biol. Chem."},{"key":"B122","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/B978-141602971-7.10007-8","article-title":"Chapter 7 - Infectious Disease Emergencies","volume-title":"Essential Emergency Medicine","author":"Salyer","year":"2007"},{"key":"B123","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/j.1462-5822.2010.01475.x","article-title":"Evasion of innate and adaptive immune responses by influenza A virus","volume":"12","author":"Schmolke","year":"2010","journal-title":"Cell Microbiol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.apsb.2015.07.006","article-title":"New small-molecule drug design strategies for fighting resistant influenza A","volume":"5","author":"Shen","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"B125","first-page":"2758","article-title":"[Current status of research and development for anti-influenza virus drugs\u2013chemotherapy for influenza]","volume":"55","author":"Shigeta","year":"1997","journal-title":"Nihon Rinsho"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1001\/jama.2010.479","article-title":"Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States","volume":"303","author":"Siston","year":"2010","journal-title":"JAMA"},{"key":"B127","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/095632020601700403","article-title":"Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses","volume":"17","author":"Smee","year":"2006","journal-title":"Antivir Chem. Chemother."},{"key":"B128","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1128\/AAC.01012-08","article-title":"Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice","volume":"53","author":"Smee","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"B129","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1128\/AAC.00933-09","article-title":"Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice","volume":"54","author":"Smee","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"B130","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1006\/viro.1998.9273","article-title":"Inhibition of influenza virus hemagglutinin-mediated membrane fusion by a compound related to podocarpic acid","volume":"248","author":"Staschke","year":"1998","journal-title":"Virology"},{"key":"B131","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3390\/v6072531","article-title":"The treatment of influenza with antiviral drugs","volume":"168","author":"Stiver","year":"2003","journal-title":"CMAJ"},{"key":"B132","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.3390\/v6072531","article-title":"RNA virus reverse genetics and vaccine design","volume":"6","author":"Stobart","year":"2014","journal-title":"Viruses"},{"key":"B133","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.5897\/AJB10.2225","article-title":"In-ovo evaluation of the antiviral activity of methanolic root-bark extract of the African Baobab (Adansonia digitata Lin)","volume":"10","author":"Sulaiman","year":"2011","journal-title":"Afr. J. Biotechnol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.curtheres.2017.01.007","article-title":"Repurposed therapeutic agents targeting the ebola virus: A systematic review","volume":"84","author":"Sweiti","year":"2017","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"B135","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1128\/AAC.04836-14","article-title":"Characterization of a large cluster of influenza A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013-2014 influenza season in Japan","volume":"59","author":"Takashita","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B136","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3201\/eid1209.05-0979","article-title":"1918 Influenza: the mother of all pandemics","volume":"12","author":"Taubenberger","year":"2006","journal-title":"Emerg. Infect. Dis."},{"key":"B137","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1001\/jama.289.2.179","article-title":"Mortality associated with influenza and respiratory syncytial virus in the United States","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jama.292.11.1333","article-title":"Influenza-associated hospitalizations in the United States","volume":"292","author":"Thompson","year":"2004","journal-title":"JAMA"},{"key":"B139","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/jama.283.8.1016","article-title":"Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group","volume":"283","author":"Treanor","year":"2000","journal-title":"JAMA"},{"key":"B140","doi-asserted-by":"publisher","first-page":"780","DOI":"10.4103\/0253-7613.103301","article-title":"Comparison of efficacy and safety of oseltamivir and zanamivir in pandemic influenza treatment","volume":"44","author":"Tuna","year":"2012","journal-title":"Indian J. Pharmacol."},{"key":"B141","first-page":"78","article-title":"S-033188, a Small Molecule Inhibitor of Cap-dependent Endonuclease of Influenza A and B Virus, Leads to Rapid and Profound Viral Load Reduction","volume-title":"Options for the Control of Influenza IX","author":"Uehara","year":"2016"},{"key":"B142","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/B978-0-12-405880-4.00006-8","article-title":"Influenza virus resistance to antiviral therapy","volume":"67","author":"van der Vries","year":"2013","journal-title":"Adv. Pharmacol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/cid\/civ680","article-title":"The use of ebola convalescent plasma to treat ebola virus disease in resource-constrained settings: A perspective from the field","volume":"62","author":"van Griensven","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B144","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/363418a0","article-title":"Rational design of potent sialidase-based inhibitors of influenza virus replication","volume":"363","author":"von Itzstein","year":"1993","journal-title":"Nature"},{"key":"B145","doi-asserted-by":"publisher","first-page":"111841","DOI":"10.1016\/j.ejmech.2019.111841","article-title":"Design, synthesis and biological evaluation of oseltamivir derivatives containing pyridyl group as potent inhibitors of neuraminidase for influenza A","volume":"185","author":"Wang","year":"2020","journal-title":"Eur. J. Medicinal Chem."},{"key":"B146","doi-asserted-by":"publisher","first-page":"10132","DOI":"10.1096\/fj.201902793RR","article-title":"A77 1726, the active metabolite of the anti-rheumatoid arthritis drug leflunomide, inhibits influenza A virus replication in vitro and in vivo by inhibiting the activity of Janus kinases","volume":"34","author":"Wang","year":"2020","journal-title":"FASEB J."},{"key":"B147","first-page":"367","article-title":"Anti-viral therapy","volume-title":"Molecular Virology of Human Pathogenic Viruses","author":"Wang-Shick","year":"2017"},{"key":"B148","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1086\/656802","article-title":"Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial","volume":"51","author":"Watanabe","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1098\/rstb.2001.0997","article-title":"Emergence of influenza A viruses","volume":"356","author":"Webby","year":"2001","journal-title":"Philos. Trans. R Soc. Lond B Biol. Sci."},{"key":"B150","first-page":"151","article-title":"Interferon inducers","volume-title":"Annual reports in medicinal chemistry","author":"Wendell","year":"1982"},{"key":"B151","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1093\/cid\/cis1220","article-title":"Global assessment of resistance to neuraminidase inhibitors 2008-2011: the influenza resistance information study (IRIS)","volume":"56","author":"Whitley","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"B152","volume-title":"WHO recommendations for production and control of influenza vaccine (inactivated)","year":"2003"},{"key":"B153","unstructured":"Number of confirmed human cases of avian influenza A(H7N9) reported to WHO2014"},{"key":"B154","unstructured":"Situation updates - Avian influenza source2018"},{"key":"B155","unstructured":"Human infection with avian influenza A(H7N4) virus \u2013 China2018"},{"key":"B156","unstructured":"Up-to-650-000-people-die-of-respiratory-diseases-linked-to-seasonal-flu-each-year2018"},{"key":"B157","doi-asserted-by":"publisher","first-page":"e01432","DOI":"10.1128\/JVI.01432-20","article-title":"Discovery of a novel specific inhibitor targeting influenza A virus nucleoprotein with pleiotropic inhibitory effects on various steps of the viral life cycle","volume":"95","author":"Yang","year":"2021","journal-title":"J. Virol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3390\/v12020225","article-title":"An oleanolic acid derivative inhibits hemagglutinin-mediated entry of influenza A virus","volume":"12","author":"Ye","year":"2020","journal-title":"Viruses"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00396-13","article-title":"Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R\/K viral population","volume":"4","author":"Yen","year":"2013","journal-title":"MBio"},{"key":"B160","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s007050050552","article-title":"Identification of a novel HA conformational change inhibitor of human influenza virus","volume":"144","author":"Yoshimoto","year":"1999","journal-title":"Arch. Virol."},{"key":"B161","doi-asserted-by":"publisher","first-page":"9296","DOI":"10.1128\/JVI.00781-09","article-title":"A one-plasmid system to generate influenza virus in cultured chicken cells for potential use in influenza vaccine","volume":"83","author":"Zhang","year":"2009","journal-title":"J. Virol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3851\/IMP1715","article-title":"Aprotinin, a protease inhibitor, suppresses proteolytic activation of pandemic H1N1v influenza virus","volume":"21","author":"Zhirnov","year":"2011","journal-title":"Antivir Chem. Chemother."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1269344\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T05:54:38Z","timestamp":1701237278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1269344\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,29]]},"references-count":162,"alternative-id":["10.3389\/fcimb.2023.1269344"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2023.1269344","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,29]]},"article-number":"1269344"}}